ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression

Jang,Ji-Young; Jeon,Yoon-Kyung; Lee,Choong-Eun; Kim,Chul-Woo

doi:10.3892/ijo.2012.1736

ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression

Authors:
- Ji-Young Jang
- Yoon-Kyung Jeon
- Choong-Eun Lee
- Chul-Woo Kim
View Affiliations

Affiliations: Tumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea, Laboratory of Immunology, Department of Biological Science, Sungkyunkwan University, Suwon 440-746, Republic of Korea, Department of Pathology, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea
Published online on: December 13, 2012 https://doi.org/10.3892/ijo.2012.1736
Pages: 574-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Suppressor of cytokine signaling 1 (SOCS1) is a negative regulator of Janus kinase and the signal transducer and activation of transcription (Jak-STAT) pathway. SOCS-1 is known to be silenced by aberrant promoter methylation in human hepatocellular carcinoma (HCC) during early tumorigenesis, therefore, a strategy to restore SOCS1 expression can be utilized for cancer therapy. Here, we examined the influence of adenine nucleotide translocase 2 (ANT2) suppression by short-hairpin RNA (shRNA) on SOCS1 expression and its downstream effect in HCC. ANT2 shRNA treatment led to restoration of SOCS1 expression along with its promoter demethylation in Hep3B cells, which was accompanied by decreased DNA methyltransferase 1 (DNMT1) activity through the suppression of Ras/PI3K/Akt signaling. Restoration of SOCS1 by ANT2 knockdown, subsequently, inhibited STAT3 activity and downregulated the expression of miR-21, which has been reported to be an important onco-miR in HCC. Downregulation of miR-21 efficiently suppressed Hep3B cell proliferation in vitro with a comparable level to ANT2 shRNA treatment. ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.

View Figures

View References

1.	Yang JD and Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
3.	Blum HE: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 11:7391–7400. 2005.PubMed/NCBI
4.	Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, Remy R, Xie ZH, Reed JC and Kroemer G: The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med. 187:1261–1271. 1998. View Article : Google Scholar : PubMed/NCBI
5.	Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC and Kroemer G: Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 281:2027–2031. 1998. View Article : Google Scholar : PubMed/NCBI
6.	Dolce V, Scarcia P, Iacopetta D and Palmieri F: A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue. FEBS Lett. 579:633–637. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Lunardi J and Attardi G: Differential regulation of expression of the multiple ADP/ATP translocase genes in human cells. J Biol Chem. 266:16534–16540. 1991.PubMed/NCBI
8.	Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E and Brenner C: Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 66:9143–9152. 2006.PubMed/NCBI
9.	Faure Vigny H, Heddi A, Giraud S, Chautard D and Stepien G: Expression of oxidative phosphorylation genens in renal tumors and tumoral cell lines. Mol Carcinog. 16:165–172. 1996.PubMed/NCBI
10.	Chevrollier A, Loiseau D, Chabi B, Renier G, Donay O, Malthiery Y and Stepien G: ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr. 37:307–316. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Chevrollier A, Loiseau D, Gautier F, Malthlery Y and Stepien G: ANT2 expression under hypoxic conditions produces opposite cell-cycle behavior in 143B and HepG2 cancer cells. Mol Carcinog. 42:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Chevrollier A, Loiseau D and Stepien G: What is the specific role of ANT2 in cancer cells? Med Sci (Paris). 21:156–161. 2005.(In French).
13.	Jang JY, Choi Y, Jeon YK and Kim CW: Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res. 10:R112008. View Article : Google Scholar : PubMed/NCBI
14.	Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Singal R and Ginder GD: DNA methylation. Blood. 93:4059–4070. 1999.PubMed/NCBI
16.	Robertson KD and Jones PA: DNA methylation: past, present and future directions. Carcinogenesis. 21:461–467. 2000. View Article : Google Scholar : PubMed/NCBI
17.	Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J. 334:297–314. 1998.PubMed/NCBI
19.	Imada K and Leonard WJ: The Jak-STAT pathway. Mol Immunol. 37:1–11. 2000. View Article : Google Scholar
20.	Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA and Hilton DJ: Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol. 66:588–592. 1999.PubMed/NCBI
21.	Nicola NA and Greenhalgh CJ: The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol. 28:1105–1112. 2000. View Article : Google Scholar : PubMed/NCBI
22.	He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 100:14133–14138. 2003. View Article : Google Scholar : PubMed/NCBI
23.	He B, You L, Xu Z, Mezieres J, Lee AY and Jablons DM: Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin Lung Cancer. 5:366–370. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C and Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 24:6699–6708. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Chu PY, Yeh CM, Hsu NC, Chang YS, Chang JG and Yeh KT: Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
26.	Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA and Gores GJ: Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 42:1329–1338. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Konnikova L, Kotecki M, Kruger MM and Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 3:1–9. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 101:1535–1542. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G and Klein B: A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene. 22:2950–2959. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J and Bernard OA: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 278:1309–1312. 1997. View Article : Google Scholar : PubMed/NCBI
32.	Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
33.	Cooney RN: Suppressors of cytokine signaling (SOCS): inhibitors of the Jak/STAT pathway. Shock. 17:83–90. 2002. View Article : Google Scholar : PubMed/NCBI
34.	Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T and Nakao A: Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clinical Cancer Res. 9:5295–5298. 2003.PubMed/NCBI
35.	Sun L, Hui AM, Kanai Y, Sakamoto M and Hirohashi S: Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res. 88:1165–1170. 1997. View Article : Google Scholar : PubMed/NCBI
36.	Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H and Hirohashi S: Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology. 33:561–568. 2001. View Article : Google Scholar
37.	Kanai K, Ushijima S, Kondo Y, Nakanishi Y and Hirohashi S: DNA methyltransferase expression and DNA methylation of CpG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer. 91:205–212. 2001. View Article : Google Scholar : PubMed/NCBI
38.	Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C, Ramaswamy B, Shapiro CL, Lin HJL, Cheng ASL, Jin VX and Huang TH: Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res. 71:1752–1762. 2011. View Article : Google Scholar : PubMed/NCBI
39.	Zhang B, Wang Q and Pan X: MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 210:279–289. 2007. View Article : Google Scholar : PubMed/NCBI
40.	Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G and Liu Y: miR2 Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 37:D98–D104. 2009. View Article : Google Scholar : PubMed/NCBI
41.	Meng F, Enson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Hatley ME, Patrick DM, Garcia MR, Richardson JA, Duby RB, van Rooij E and Olson EN: Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 18:282–293. 2010. View Article : Google Scholar : PubMed/NCBI